Roth Capital Analysts Give BioDelivery Sciences International, Inc. (BDSI) a $5.00 Price Target

Roth Capital set a $5.00 price objective on BioDelivery Sciences International, Inc. (NASDAQ:BDSI) in a research note released on Monday. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other equities analysts have also issued reports on BDSI. HC Wainwright set a $5.00 price target on BioDelivery Sciences International and gave the stock a buy rating in a research report on Thursday, August 10th. Piper Jaffray Companies set a $4.00 price objective on BioDelivery Sciences International and gave the stock a buy rating in a report on Wednesday, August 9th. Cantor Fitzgerald reiterated an overweight rating and issued a $4.50 price objective on shares of BioDelivery Sciences International in a report on Monday, August 14th. ValuEngine cut BioDelivery Sciences International from a hold rating to a sell rating in a report on Friday, September 1st. Finally, Zacks Investment Research cut BioDelivery Sciences International from a buy rating to a hold rating in a report on Monday, July 17th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $4.29.

BioDelivery Sciences International (NASDAQ BDSI) opened at $2.25 on Monday. The company has a quick ratio of 1.07, a current ratio of 1.28 and a debt-to-equity ratio of 1.89. BioDelivery Sciences International has a 1 year low of $1.50 and a 1 year high of $3.60.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.01. BioDelivery Sciences International had a return on equity of 33.83% and a net margin of 10.40%. The business had revenue of $11.25 million for the quarter, compared to analyst estimates of $9.40 million. During the same period last year, the company earned ($0.30) EPS. BioDelivery Sciences International’s revenue for the quarter was up 215.1% compared to the same quarter last year. analysts predict that BioDelivery Sciences International will post 0.16 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/roth-capital-analysts-give-biodelivery-sciences-international-inc-bdsi-a-5-00-price-target/1780929.html.

In other news, insider Mark A. Sirgo sold 201,373 shares of the firm’s stock in a transaction that occurred on Thursday, September 21st. The stock was sold at an average price of $2.84, for a total value of $571,899.32. Following the completion of the transaction, the insider now owns 1,509,262 shares in the company, valued at approximately $4,286,304.08. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Mark A. Sirgo sold 65,405 shares of the firm’s stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $2.75, for a total value of $179,863.75. Following the completion of the transaction, the chief executive officer now owns 1,509,262 shares of the company’s stock, valued at approximately $4,150,470.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 402,127 shares of company stock valued at $1,142,798. Company insiders own 9.00% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in BDSI. Wells Fargo & Company MN lifted its stake in shares of BioDelivery Sciences International by 138.2% in the 3rd quarter. Wells Fargo & Company MN now owns 35,506 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 20,599 shares during the period. Valley National Advisers Inc. lifted its stake in shares of BioDelivery Sciences International by 59.0% in the 2nd quarter. Valley National Advisers Inc. now owns 37,715 shares of the specialty pharmaceutical company’s stock valued at $106,000 after purchasing an additional 14,000 shares during the period. JPMorgan Chase & Co. purchased a new position in shares of BioDelivery Sciences International in the 3rd quarter valued at approximately $116,000. Cutter & CO Brokerage Inc. lifted its stake in shares of BioDelivery Sciences International by 2.4% in the 2nd quarter. Cutter & CO Brokerage Inc. now owns 43,430 shares of the specialty pharmaceutical company’s stock valued at $122,000 after purchasing an additional 1,000 shares during the period. Finally, Advisor Group Inc. lifted its stake in shares of BioDelivery Sciences International by 42.1% in the 2nd quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock valued at $126,000 after purchasing an additional 13,341 shares during the period. Institutional investors own 40.68% of the company’s stock.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Toronto Blue Jays Launch Internal Investigation on PED Use
Toronto Blue Jays Launch Internal Investigation on PED Use
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player


Leave a Reply

 
© 2006-2017 BBNS.